Anaemia characterises patients with myelofibrosis harbouring Mpl mutation - PubMed (original) (raw)
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation
Paola Guglielmelli et al. Br J Haematol. 2007 May.
Free article
Abstract
The clinical and haematological phenotype of patients with myelofibrosis harbouring MPL(W515L/K) mutation has not been thoroughly investigated. Of 217 myelofibrosis subjects, 18 (8.2%) had an MPL mutation, four of which (22%) co-existed with JAK2(V617F) mutation. When compared with MPL wild-type patients, irrespective of JAK2(V617F) status, those with MPL(W515L/K), were more frequently female, were older (61 years vs. 57 years; P = 0.02), presented with more severe anaemia (haemoglobin, 101 g/l vs. 121 g/l; P = 0.002) and were more likely to require regular transfusional support (P = 0.012). These data indicate that MPL mutation in myelofibrosis characterises patients with more severe anaemic phenotype.
Similar articles
- JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H. Hussein K, et al. Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17. Exp Hematol. 2009. PMID: 19616600 - Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A. Pardanani A, et al. Leukemia. 2011 Dec;25(12):1834-9. doi: 10.1038/leu.2011.161. Epub 2011 Jun 21. Leukemia. 2011. PMID: 21691276 - JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A, Bieniaszewska M, Hellmann A, Limon J. Siemiatkowska A, et al. Leuk Res. 2010 Mar;34(3):387-9. doi: 10.1016/j.leukres.2009.06.017. Epub 2009 Jul 29. Leuk Res. 2010. PMID: 19643476 - [New insight into pathogenesis of idiopathic myelofibrosis--review].
Xu ZQ, Sun XM. Xu ZQ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Dec;15(6):1330-4. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007. PMID: 18088495 Review. Chinese. - Important Pathologic Considerations for Establishing the Diagnosis of Myelofibrosis.
Salama ME. Salama ME. Hematol Oncol Clin North Am. 2021 Apr;35(2):267-278. doi: 10.1016/j.hoc.2020.11.002. Epub 2021 Jan 14. Hematol Oncol Clin North Am. 2021. PMID: 33641868 Review.
Cited by
- Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine.
Tashkandi H, Younes IE. Tashkandi H, et al. Cancers (Basel). 2024 Apr 26;16(9):1679. doi: 10.3390/cancers16091679. Cancers (Basel). 2024. PMID: 38730632 Free PMC article. Review. - Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.
Combaluzier S, Quessada J, Abbou N, Arcani R, Tichadou A, Gabert J, Costello R, Loosveld M, Venton G, Berda-Haddad Y. Combaluzier S, et al. Cells. 2023 Mar 20;12(6):946. doi: 10.3390/cells12060946. Cells. 2023. PMID: 36980287 Free PMC article. Review. - Development of a Real-Time qPCR Assay for Detection of Common MPL Mutations in Myeloproliferative Neoplasms (MPNS).
Ullah N, Khan SN, Umair M, Khan AA, Liu X, Khattak AA, Yousafzai YM. Ullah N, et al. Appl Biochem Biotechnol. 2022 Dec;194(12):5907-5917. doi: 10.1007/s12010-022-04051-y. Epub 2022 Jul 15. Appl Biochem Biotechnol. 2022. PMID: 35838887 - Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.
Tavares RS, Nonino A, Pagnano KBB, Nascimento ACKVD, Conchon M, Fogliatto LM, Funke VAM, Bendit I, Clementino NCD, Chauffaille MLLF, Bernardo WM, Santos FPS. Tavares RS, et al. Hematol Transfus Cell Ther. 2019 Jul;41 Suppl 1(Suppl 1):1-73. doi: 10.1016/j.htct.2019.03.001. Epub 2019 May 10. Hematol Transfus Cell Ther. 2019. PMID: 31248788 Free PMC article. No abstract available. - Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P. Pacilli A, et al. Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x. Blood Cancer J. 2018. PMID: 30467377 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous